A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.

Show other versions (1)

BACKGROUND: Poly adenosine diphosphate (ADP)-ribose polymerase (PARP) is essential in cellular processing of DNA damage via the base excision repair pathway (BER). The PARP inhibition can be directly cytotoxic to tumour cells and augments the anti-tumour effects of DNA-damaging agents. This study ev...

Full description

Bibliographic Details
Main Authors: Khan, O, Gore, M, Lorigan, P, Stone, J, Greystoke, A, Burke, W, Carmichael, J, Watson, A, McGown, G, Thorncroft, M, Margison, G, Califano, R, Larkin, J, Wellman, S, Middleton, MR
Format: Journal article
Language:English
Published: 2011

Similar Items